Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million
Key Points
The transaction was valued at $1 million.
The sale reduced the director's direct equity holdings by 9%.
Perry maintains direct ownership of approximately 111,000 shares.
Michael S. Perry, a Director at Arrowhead Pharmaceuticals (NASDAQ:ARWR), sold 11,600 shares of common stock on Aug. 18, 2026, according to an SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $1 million |
| Shares sold | 11,600 |
| Post-transaction shares (directly held) | 111,459 |
| Post-transaction value | $9.8 million |
Transaction value based on SEC Form 4 weighted average sale price ($87.30); post-transaction value based on Aug. 18, 2026, market close ($87.90).
Key questions
- What were the specific execution details of this open-market sale?
The shares were disposed of in multiple transactions at prices ranging from $87.20 to $87.44, with the reporting person providing full trade data to the company and the SEC upon request. - How does this transaction impact the insider's total stake in the company?
By selling 11,600 shares, the director liquidated 9% of his direct holdings. However, he remains a stakeholder with 0.0791% of the company's equity and continues to hold common stock underlying unvested restricted stock units. - What is the current market valuation context for Arrowhead Pharmaceuticals?
The Pasadena-based biotechnology company maintains a market capitalization of $12.2 billion, with shares priced at $89.41 as of the Aug. 19, 2026, market close. - What are the fundamental financial metrics for the firm?
Arrowhead Pharmaceuticals reported trailing twelve-month revenue of $669.5 million and a net loss of $320 million as it continues to advance a therapeutic pipeline centered on RNA interference technology.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-19) | $89.41 |
| Market Capitalization | $12.6 billion |
| Revenue (TTM) | $669.5 million |
| Net Income (TTM) | -$320 million |
Company Snapshot
- Arrowhead Pharmaceuticals develops innovative biopharmaceutical treatments leveraging RNA interference (RNAi) technology, with a clinical pipeline focused on complex, challenging-to-treat diseases, and generates revenue through therapeutic development and commercialization.
- The company operates as a discovery-stage to clinical-stage biopharmaceutical enterprise, advancing multiple therapeutic candidates through clinical trials to achieve regulatory approval and subsequent commercialization in the United States market.
- Arrowhead targets patients with rare genetic diseases and complex liver conditions, including alpha-1 antitrypsin deficiency, positioning itself in the specialty pharmaceutical and orphan drug markets where unmet medical needs remain substantial.
Arrowhead Pharmaceuticals, founded in 1989 and headquartered in Pasadena, California, represents a clinical-stage biopharmaceutical company with a market capitalization of $12.2 billion and 711 employees. The company's strategic focus on RNAi-based therapeutics provides a differentiated technological platform for addressing genetic and metabolic disorders with limited treatment options. With TTM revenue of $669.5 million and continued investment in its pipeline, Arrowhead demonstrates the capital-intensive nature of biopharmaceutical development. However, the company remains positioned to capture significant value upon successful advancement and commercialization of its clinical candidates.
What this transaction means for investors
Over the last 12 months, the Arrowhead stock price has skyrocketed 217.7%. In comparison, over the same period, the S&P 500 has climbed 18.8%. With that context and the amount of shares sold, this appears to be a routine transaction from Perry. While he did sell 11,600 shares, he still directly holds 111,459 shares, signaling continued confidence in the company. The sale is likely just Perry taking some profits off the table, and not something shareholders should read too much into.
For what's ahead for the company, analysts are bullish, but shareholders may still want to keep their expectations in check. With the stock already climbing over 217.7% over the past year, it will be difficult to keep that pace. According to CNN, all 14 who cover the stock rate it a buy. Among those analysts, the median one-year price target is $109.50, representing a 26.8% gain from the current price of $86.34. The highest price target, $126, would represent a gain of nearly 46%. The lowest price target, $100, still would represent a gain of 15.8%.
Jack Delaney has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.